Loading company…
Riskpilot
← Back to search
Sign in
Get full access
SYMBIOTEK AS
AS
Active
Org 934400305
Baseveien 15, 6531 Averøy
Business and other management consultancy activities · NACE 7020
Est. 2024
— employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
NOK 0
EBITDA margin
—
-379% vs 2024
Equity ratio
5.7%
Financial strength
Net profit 2025
NOK -19K
-381% vs 2024
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
NOK 0
—
EBITDA
NOK -19K
-379%
Net profit
NOK -19K
-381%
Total assets
NOK 26K
+27%
Equity
NOK 1K
-93%
Employees
—
—
Company information
Legal name
SYMBIOTEK AS
Org number
934400305
Legal form
Aksjeselskap
NACE code
7020 · Business and other management consultancy activities
Founded
1. november 2024
Share capital
NOK 30 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utrede og utvikle symbioser tilknyttet industrietableringer i averøy og hva dermed står i forbindelse.
Contact
Address
Baseveien 15, 6531 Averøy
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Business and other management consultancy activities
Companies in Averøy
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2024
0M
2025
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2024
0M
2025
Income statement
NOK thousands
Item
2024
2025
Revenue
0
0
Staff expenses
−0
−0
EBITDA
−4
−19
Depreciation & amort.
−0
−0
EBIT
−4
−19
Net financials
0
−0
Profit before tax
−4
−19
Tax
−0
−0
Net profit
−4
−19
Balance sheet
NOK thousands
Item
2024
2025
Total assets
20
26
Equity
20
1
Long-term debt
0
0
Short-term debt
0
24
Total debt
0
24
Financial ratios
5-year trend
EBITDA margin
-1879100.0%
This company
15.8%
Market median
-11893138% vs market
2024
2025
Equity ratio
5.7%
This company
38.2%
Market median
-85% vs market
2024
2025
Return on equity
-1291.2%
This company
18.4%
Market median
-7117% vs market
2024
2025
Net profit margin
-1883800.0%
This company
8.1%
Market median
-23256890% vs market
2024
2025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2024
2025
Debt / equity
16.65×
This company
0.62×
Market median
-2585% vs market
2024
2025
Annual reports & filings
Annual report 2025
Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-10-01 – 2024-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
SA
Siri Aarland
Chief Executive Officer
Chief Executive Officer
2025
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
KB
Kristian Brekke Djuve
Chairman
2024
OJ
Ole Jørgen Marvik
Chairman
2025
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Bio3 As
Company
100%
100%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Atlanticon Bedriftsrådgivning As
Sirø Invest As
Bio3 As
SYMBIOTEK AS
(this company)
Board network connections
Board members of SYMBIOTEK AS also hold positions in
0
other companies.
Person
Role here
Other companies
Siri Aarland
Chief Executive Officer
0 companies
Kristian Brekke Djuve
Chairman
0 companies
Ole Jørgen Marvik
Chairman
0 companies